An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds

Analytical Biochemistry

Volumn 333, Issue 2, 2004, Pages 372-380

  Boshuizen, Ronald S ^a   Langeveld, Jan P M ^b   Salmona, Mario ^c   Williams, Alun ^d   Meloen, Rob H ^a,e   Langedijk, Johannes P M ^a  

^a Pepscan Systems   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; Amyloid; BSE; High throughput assay; Prion; PrP106 126; Tetracycline; Thioflavin S

Indexed keywords

ACTIVATION ANALYSIS; DIAGNOSIS; FLUORESCENCE; GLYCOPROTEINS; PEPTIDES;

ALZHEIMER'S DISEASE; AMYLOID; HIGH-THROUGHPUT ASSAYS; PRION; PRP106-126; TETRACYCLINE; THIOFLAVIN S;

NEURODEGENERATIVE DISEASES;

AMYLOID; AMYLOID BETA PROTEIN[1-42]; BUFFER; DIRECT YELLOW 7; PHOSPHATE; POLYSTYRENE; PRION PROTEIN; SYNTHETIC PEPTIDE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CORRELATION ANALYSIS; FIBER; FLUORESCENCE ANALYSIS; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; REPRODUCIBILITY; SCREENING TEST;

EID: 4644336914     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2004.06.011     Document Type: Article

References (58)

1. S.B. Prusiner Novel proteinaceous infectious particles cause scrapie Science 216 1982 136 144
2. Sc-like conformation in living cells Nat. Cell Biol. 1 1999 358 361
3. M.E. Bruce, P.A. McBride, and C.F. Farquhar Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie Neurosci. Lett. 102 1989 1 6
4. Sc in scrapie-infected hamster brain is spatially and temporally related to histopathology and infectivity titer Prog. Clin. Biol. Res. 317 1989 601 618
5. F. Gray, F. Chretien, H. Adle-Biassette, A. Dorandeu, T. Ereau, M.B. Delisle, N. Kopp, J.W. Ironside, and C. Vital Neuronal apoptosis in Creutzfeldtâ€"Jakob disease J. Neuropathol. Exp. Neurol. 58 1999 321 328
6. G. Forloni, N. Angeretti, R. Chiesa, E. Monzani, M. Salmona, O. Bugiani, and F. Tagliavini Neurotoxicity of prion protein fragment Nature 362 1993 543 546
7. M. Salmona, P. Malesani, L. De Gioia, S. Gorla, M. Bruschi, A. Molinari, F. Della Vedova, B. Pedrotti, M.A. Marraris, T. Awan, O. Bugiani, G. Forloni, and F. Tagliavini Molecular determinants of the physicochemical properties of a critical prion region comprising residues 106â€"126 Biochem. J. 342 1999 207 214
8. L. De Gioia, C. Selvaggini, E. Ghibaudi, L. Diomede, O. Bugiani, G. Forloni, F. Tagliavini, and M. Salmona Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106†"126 of the prion protein J. Biol. Chem. 269 1994 7859 7862
9. M.F. Jobling, L.R. Stewart, A.R. White, C. McLean, A. Friedhuber, F. Maher, K. Beyreuther, C.L. Masters, C.J. Barrow, S.J. Collins, and R. Cappai The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106â€"126 J. Neurochem. 73 1999 1557 1565
10. T. Florio, D. Paludi, V. Villa, D. Rossi, R. Principe, A. Corsaro, E. Millo, G. Damonte, C. D'Arrigo, C. Russo, G. Schettini, and A. Aceto Contribution of two conserved glycine residues to fibrillogenesis of the 106â€"126 prion protein fragment: evidence that a soluble variant of the 106â€"126 peptide is neurotoxic J. Neurochem. 85 2003 62 72
11. J.M. Peyrin, C.I. Lasmezas, S. Haik, F. Tagliavini, M. Salmona, A. Williams, D. Richie, J.P. Deslys, and D. Dormont Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines Neuroreport 10 1999 723 729
12. C.F. Farquhar, and A.G. Dickinson Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection J. Gen. Virol. 67 1986 463 473
13. R.H. Kimberlin, and C.A. Walker Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions Antimicrob. Agents Chemother. 30 1986 409 413
14. B. Caughey, and G.J. Raymond Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells J. Virol. 67 1993 643 650
15. B.C.H. May, A.T. Fafarman, S.B. Hong, M. Rogers, L.W. Deady, S.B. Prusiner, and F.E. Cohen Potent inhibition of scrapie prion replication in cultured cells by bis-acridines Proc. Natl. Acad. Sci. USA 100 2003 3416 3421
16. A. Barret, F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. DeLuigi, L. Limido, S. Suardi, G. Rossi, F. Auvré, K.T. Adjou, N. Salès, A. Williams, C. Lasmézas, and J.P. Deslys Evaluation of quinacrine treatment for prion diseases J. Virol. 77 2003 8462 8469
17. W.S. Caughey, L.D. Raymond, H. Motohiro, and B. Caughey Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines Proc. Natl. Acad. Sci. USA 95 1998 12117 12122
18. A. Lorenzo, and B.A. Yankner β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red Proc. Natl. Acad. Sci. USA 91 1994 12243 12247
19. G. Poli, W. Ponti, G. Carcassola, F. Ceciliani, L. Colombo, P. Dall'Ara, M. Gervasoni, M.L. Giannino, P.A. Martino, C. Pollera, S. Villa, and M. Salmona In vitro evaluation of the anti-prionic activity of newly synthesized Congo red derivatives Arzneimittelforschung 53 2003 875 888
20. res accumulation in the brain of scrapie-infected hamsters J. Comp. Pathol. 122 2000 3 8
21. S. Supattapone, H.O. Nguyen, F.E. Cohen, S.B. Prusiner, and M.R. Scott Elimination of prions by branched polyamines and implications for therapeutics Proc. Natl. Acad. Sci. USA 96 1999 14529 14534
22. S. Supattapone, H. Wille, L. Uyechi, J. Safar, P. Tremblay, F.C. Szoka, F.E. Cohen, S.B. Prusiner, and M.R. Scott Branched polyamines cure prion-infected neuroblastoma cells J. Virol. 75 2001 3453 3461
23. C. Soto, G.P. Saborio, and B. Permanne Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer’s disease therapy Acta Neurol. Scand. Suppl. 176 2000 90 95
24. P. Tremblay, Z. Meiner, M. Galou, C. Heinrich, C. Petromilli, T. Lisse, J. Cayetano, M. Torchia, W. Mobley, H. Bujard, S.J. DeArmond, and S.B. Prusiner Doxycycline control of prion protein transgene expression modulates prion disease in mice Proc. Natl. Acad. Sci. USA 95 1998 12580 12585
25. Sc in vitro J. Mol. Biol. 300 2000 1309 1322
26. G. Forloni, L. Colombo, L. Girola, F. Tagliavini, and M. Salmona Anti-amyloidogenic activity of tetracyclines: study in vitro FEBS Lett. 487 2001 404 407
27. G. Forloni, S. Iussich, T. Awan, L. Colombo, N. Angeretti, L. Girola, I. Bertani, G. Poli, M. Caramelli, M.G. Bruzzone, L. Farina, L. Limido, G. Rossi, G. Giaccone, J.W. Ironside, O. Bugiani, M. Salmona, and F. Tagliavini Tetracyclines affect prion infectivity Proc. Natl. Acad. Sci. USA 99 2002 10849 10854
28. H. Bennhold Specific staining of amyloid by Congo red München Med. Wochnschr. 69 1922 1537 1538
29. E.M. Castano, J. Ghiso, F. Prelli, P.D. Gorevic, A. Migheli, and B. Frangione In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease beta-protein Biochem. Biophys. Res. Commun. 141 1986 782 789
30. G.G. Glenner, E.D. Eanes, and D.L. Page The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation J. Histochem. Cytochem. 20 1972 821 826
31. J.H. Cooper Selective amyloid staining as a function of amyloid composition and structure: Histochemical analysis of the alkaline Congo red, standardized Toluidine blue, and iodine methods Lab. Invest. 31 1974 232 238
32. W.E. Klunk, R.F. Jacob, and R.P. Mason Quantifying amyloid by Congo red spectral shift assay Methods Enzymol. 309 1999 285 305
33. P.F. Vassar, and C.F.A. Culling Fluorescent stains, with special reference to amyloid and connective tissues Arch. Pathol. 68 1959 487 498
34. B. Urbanc, L. Cruz, R. Le, J. Sanders, K. Hsiao Ashe, K. Duff, H.E. Stanley, M.C. Irizarry, and B.T. Hyman Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer’ s disease Proc. Natl. Acad. Sci. USA 99 2002 13990 13995
35. J.R. Hobbs, and A.D. Morgan Fluorescence microscopy with thioflavin T in the diagnosis of amyloid J. Pathol. Bacteriol. 86 1963 437 442
36. T. Heyl Amyloid staining with thioflavin T in dermatopathology Trans. St. John’s Hosp. Derm. Soc. 52 1966 84 87
37. P. Schwartz, J. Kurucz, and A. Kurucz Morphologische und pathogenetische Untersuchungen über Veränderungen in Greisalter Zentralblad Allgemeine Pathologie pathologische Anatomie 106 1964 320 332
38. A. Pomerance The pathology of senile cardiac amyloidosis J. Pathol. Bacteriol. 91 1966 357 367
39. G.T. Westermark, K.H. Johnson, and P. Westermark Staining methods for identification of amyloid in tissue Methods Enzymol. 309 1999 3 25
40. S.M. Saeed, and G. Fine Thioflavin T for amyloid detection Am. J. Clin. Pathol. 47 1967 588 593
41. D. Stiller, D. Katenkamp, and K. Thoss Staining mechanism of thioflavin T with special reference to localization of amyloid Acta Histochem. 42 1972 234 245
42. Y-M. Lin, R. Raffen, Y. Zhou, C.S. Cassidy, M.T. Flavin, and F.J. Stevens Amyloid fibril formation in microwell plates for screening of inhibitors Amyloid: J. Protein Fold. Disord. 8 2002 182 193
43. D. Stiller, and D. Katenkamp Untersuchungen zum fluoreszenzoptischen Nachweis van Amyloid durch Thioflavin S Zentralblad Allgemeine Pathologie pathologische Anatomie 113 1970 451 465
44. G. Kelenyi Thioflavin S fluorescent and Congo red anisotropic stainings: the histologic demonstration of amyloid Acta Neuropathol. 7 1967 336 348
45. C.B. Caputo, P.E. Fraser, I.E. Sobel, and D.A. Kirschner Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of beta-amyloid protein precursor Arch. Biochem. Biophys. 292 1992 199 205
46. F. Tagliavini, F. Prelli, L. Verga, G. Giaccone, R. Sarma, P. Gorevic, B. Ghetti, F. Passerini, E. Ghibaudi, G. Forloni, M. Salmona, and B. Frangione Synthetic peptides homologous to prion protein residues 106â€" 147 form amyloid-like fibrils in vitro Proc. Natl. Acad. Sci. USA 90 1993 9678 9682
47. L.B. Porteous The pituitary acidophil: a comparison of its staining reactions with anti-human growth hormone and thioflavin T J. Pathol. Bacteriol. 91 1966 539 543
48. W.C. Peterson Thioflavin T reactivity in calcifying epithelioma of Malherbe Arch. Dermatol. 97 1968 340 341
49. G.G. Glenner, E.D. Eanes, J.D. Termine, H.A. Bladen, and R.P. Linke The structural characteristics of some proteins having the properties of Congo red stained amyloid fibrils J. Histochem. Cytochem. 21 1973 406
50. R. Khurana, V.N. Uversky, L. Nielsen, and A.L. Fink Is Congo red an amyloid specific dye? J. Biochem. Chem. 276 2001 22715 22721
51. H. Naiki, K. Higuchi, M. Hosokawa, and T. Takeda Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T Anal. Chem. 177 1989 244 249
52. H.A. Kretzschmar, L.E. Stowring, D. Westaway, W.H. Stubblebine, S.B. Prusiner, and S.J. Dearmond Molecular cloning of a human prion protein cDNA DNA 5 1986 315 324
53. C. Locht, B. Chesebro, R. Race, and J.M. Keith Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent Proc. Natl. Acad. Sci. USA 83 1986 6372 6376
54. S. Haik, J.M. Peyrin, L. Lins, M.Y. Rosseneu, R. Brasseur, J.P. Langeveld, F. Tagliavini, J.P. Deslys, C. Lasmezas, and D. Dormont Neurotoxicity of the putative transmembrane domain of the prion protein Neurobiol. Dis. 7 2000 644 656
55. C.G. Fields, D.H. Lloyd, R.L. MacDonald, K.M. Otteson, and R.L. Noble HBTU activation for automated Fmoc solid-phase peptide synthesis Peptide Res. 4 1991 95 101
56. Y.Z. Zheng, R. Webb, P.F. Greenfield, and S. Reid Improved method for counting virus and virus like particles J. Virol. Methods 62 1996 153 159
57. K.M. Lundberg, C.J. Stenland, F.E. Cohen, S.B. Prusiner, and G.L. Millhauser Kinetics and mechanism of amyloid formation by the prion protein H1 peptide as determined by time-dependent ESR Chem. Biol. 4 1997 345 355
58. G. Forloni, M.R. Vari, L. Colombo, O. Bugiani, F. Tagliavini, and M. Salmona Prion diseases: time for a therapy? Curr. Med. Chem. Immunol. Endocrinol. Metab. Agents 3 2003 185 197